Explorer les evidences

93 %Among 128 genotyped samples from timepoint 1, 93% (n = 119) demonstrated extensive drug resistance affecting second-line antiretroviral therapy.

KenyaVIH/sidaobservé 2010-2013publié 2022Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 13 observations

119 individualsAmong 348 women in a 2-year study of young women at high HIV risk in Thika and Kisumu, Kenya, 119 (34%) followed a moderate but declining PrEP adherence trajectory.

KenyaVIH/sidapublié 2023AIDS and behaviorPubMeddocument de 5 observations

39,2 %Of 7,488 community residents surveyed, 1,474 (39.2%) intervention participants tested positive for malaria.

Kenyapaludismepublié 2025PLOS global public healtheurope_pmcdocument de 14 observations

53,8 %Treatment abandonment due to costs was reported in 53.8% of cancer patients in Kenya.

Kenyacancer (non précisé)PubMeddocument de 11 observations

AFRICOS participants had significantly higher rates of CD4 < 200 compared to DC Cohort participants.

KenyaVIH/sidapublié 2022PloS onePubMeddocument de 13 observations

73 %District managers responded to 73% of rapid diagnostic test (RDT) stock-out signals by redistributing commodities between facilities.

Kenyapaludismepublié 2013PloS oneeurope_pmcdocument de 10 observations

2,5 %In the last quarter of the trial, 2.5% (37/1507) of visits with eligible family planning clients at intervention facilities included cervical cancer screening.

Kenyacancer du col de l'utéruspublié 2023Implementation science : ISeurope_pmcdocument de 5 observationsDOI 10.1186/s13012-023-01322-y

0,08 prevalence_differenceThe pooled prevalence difference for anemia later in pregnancy (26–30 weeks) among women with first-trimester malaria was 0.08.

Kenyaanémie · paludismeobservé 26-30 weekspublié 2024PloS onePubMeddocument de 14 observations

1,3 %Among pregnant women, the co-infection prevalence with Schistosoma haematobium and hookworm or Trichuris trichiura was 1.3% in Kwale County, Coastal Kenya.

Kenyaankylostomiase · schistosomiasepublié 2022BMC public healthPubMeddocument de 14 observations

92 %A pneumococcal colonization density threshold of ≥6.9 log₁₀ copies/mL had a specificity of 92% for detecting microbiologically confirmed pneumococcal pneumonia.

Kenyapneumoniepublié 2017Clinical infectious diseases : an official publication of the Infectious Diseases Society europe_pmcdocument de 7 observations

0,44 %Among 3623 individuals screened during the cross-sectional surveys, 16 (0.44%) were positive for malaria.

Kenyapaludismeobservé 2006-2007publié 2019Malaria control & eliminationeurope_pmcdocument de 5 observations

65 %Among 57 pregnant women with virologic non-suppression, 65% had HIV drug resistance mutations.

KenyaVIH/sidapublié 2021PloS onePubMeddocument de 6 observations

1 %Among 647 Kenyan women planning to conceive, 1% had severe periodontitis.

Kenyaperiodontitispublié 2022BMC oral healtheurope_pmcdocument de 6 observationsDOI 10.1186/s12903-022-02243-w

3 monthsRTS,S/AS01-induced anti-CSP IgM antibodies increased above the control group levels by month 3.

Kenyapaludismepublié 2021Malaria journalPubMeddocument de 5 observations

22,6 %Combinations of HPV types (16, 18/45) had a prevalence of 19 (22.6%) among the VIA positive women in the overall study participants.

KenyaHPV types 16, 18/45publié 2020The Pan African medical journalPubMeddocument de 5 observations

19,5 %Among 577 pregnant women attending selected Primary Health Care facilities in Kenya, 19.5% had been tested for hepatitis B virus (HBV).

Kenyahépatite Bpublié 2024Frontiers in public healthPubMeddocument de 15 observations

27,94 %In the 2015 Kenya STEPwise Survey, 27.94% of participants were classified as being overweight or obese.

Kenyaoverweight or obesityobservé 2015publié 2021Public healthPubMeddocument de 7 observations

5,7 per_100_person-yearsThe incidence of planned pregnancies among female sex workers living with HIV in Mombasa, Kenya was 5.7 per 100 person-years.

KenyaVIH/sidaobservé October 2012-April 2017publié 2020Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument de 10 observations

0,9 %Genotyping detected R561H mutation at a frequency of 0.9% in the Kelch 13 (Pfk13) gene.

Kenyapaludismepublié 2025Malaria journalPubMeddocument de 12 observations

30 per_100Antibody prevalence in adults was low (< 30%) for SE and circumsporozoite protein (CSP).

Kenyapaludismepublié 2020The American journal of tropical medicine and hygienePubMeddocument de 3 observations

Time to symptom resolution was similar between COVID-19 patients with malaria co-infection (median 9 days [IQR 5–13]) and those without (median 10 days [IQR 6–13]), with adjusted hazard ratio 1.14 (95% CI 0.91–1.42; p=0.26).

KenyaCOVID-19 · paludismepublié 2026The Lancet. Global healthPubMeddocument de 8 observations

7 %The vaccine efficacy of RTS,S/AS01 against clinical malaria was 7.0% in the per-protocol analysis over 7 years of follow-up.

Kenyapaludismepublié 2016The New England journal of medicineeurope_pmcdocument de 4 observations

The FY.4 variant resulted in localized outbreaks in Europe, North America, and Asia-Pacific.

KenyaCOVID-19publié 2025Virus evolutioneurope_pmcdocument de 4 observations

92,9 %Among 618 enrolled participants, 574 (92.9%) identified HIV counseling/testing as an advantage.

KenyaVIH/sidaobservé From February 2017 to May 2018publié 2026BMC public healthPubMeddocument de 10 observations

23,1 %The four leading underlying causes of death were HIV/AIDS (102/442 [23.1%]), hypertensive disease (41/442 [9.3%]), other cardiovascular diseases (23/442 [5.2%]), and cancer (20/442 [4.5%]).

KenyaVIH/sidaobservé 2019publié 2022PloS onePubMeddocument de 8 observations